Akero Therapeutics, Inc. (AKRO) Dividend History

Company News

• Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025

  Akero Therapeutics and HistoIndex presented new analyses from the Phase IIb HARMONY study at the EASL 2025 Congress, highlighting the potential of AI-based digital pathology in assessing histopathological response to Efruxifermin (EFX) in patients with pre-cirrhotic MASH.

  GlobeNewswire Inc.
• This Stock Just Doubled in 1 Day -- Is It Still a Buy?

  Akero Therapeutics, a biotech company developing a potential treatment for a liver disease, saw its stock soar 97% after positive midstage clinical trial results. The article discusses the company's pipeline, the unmet need in this area, and the potential for accelerated approval, while also noting the risks involved as Akero's only pipeline candidate.

  The Motley Fool

  Featured Companies: MDGL
• Akero Therapeutics CFO sells over $976k in company stock - Investing.com

  Akero Therapeutics' CFO, William Richard White, sold over $976,000 worth of company stock, while also acquiring nearly $209,000 worth of shares through option exercises. The transactions were carried out under a pre-established trading plan.

  Investing.com
• Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

  Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

  Zacks Investment Research

  Featured Companies: IONS MDGL VKTX
• Madrigal’s stock surges as FDA approves first drug for liver disease MASH

  Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.

  MarketWatch

  Featured Companies: ETNB LLY MDGL